Pharmaceutical giant Pfizer is expected to sell 50 million doses of its Covid-19 vaccine to India by the third quarter of this fiscal year as the ongoing negotiations between the company and the central government seems to be heading towards a positive conclusion.
Senior officials from the government have apparently held several discussions with senior Pfizer executives with respect to the availability of these vaccines. However, the company’s persistence towards attaining indemnity that will protect it from any sort of legal action in India has been a major stumbling block amidst the negotiations.
However, top government officers have ensured that this issue along with other matters will be clarified in the due course, Times of India reports.
The USA does not permit the export of indigenously produced Pfizer or Moderna vaccines unless Americans do not require the same. Hence, vaccination centres based in Europe are largely believed to be the source of Pfizer doses that will be delivered to India.
Meanwhile, the European Medicines Agency (EMA) has declared that the m-RNA vaccines that it has approved can neutralize the new variant that has been detected in Maharashtra. So far, the EMA has sanctioned Johnson & Johnson, Moderna, AstraZeneca and the Pfizer vaccines for the continent.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.